Sandra H.

Insightful post on the luxury brand paradox. It got me thinking that in pharma/biotech brand positioning there is a similar paradox. New Brands almost too desperately and overtly seek to establish an emotional connection with physicians at the outset without understanding the work required to obtain it. Every Brand wants to establish an emotional connection. ❤️ ✅ It's consistently delivering on an important functional benefit that puts you on the road to establishing an emotional connection. 🛣 ✅ It's a road that takes some time to establish the connection. Last Harris Poll on the subject showed that brands that "owned" an emotional connection were on average on the market for almost a decade. ⏳ ✅ It's granted by the customers. Foisting upon physicians an emotion absence of experience only engenders antibodies to your messaging and brand positioning. 🤝 Yes, it's critical to establish an emotional connection, but this has to be earned over time and granted by the customer. 🎯

25

5 commentaires

What if the key to impactful corporate giving lies in the hands of your employees? At Haleon, we’ve discovered the most meaningful community programs are those co-created along with our teams. When we transitioned from GSK to a standalone company, we had the unique opportunity to build the Haleon Community Giving Program from scratch. Guided by our global vision, we chose not to implement a top-down approach to this important foundation of the company. Instead, we tapped into the passion and ideas of our employees, letting them lead the way to help define our community involvement. Our Community Giving Program focuses on Health Inclusivity, addressing critical social issues and improving healthcare access and health literacy. From grassroots beginnings, our program has evolved through collaboration and input from our employees. The enthusiasm and engagement from our people have confirmed we’re on the right path. By co-creating with our employees, we’ve cultivated a sense of ownership and pride, aligning our corporate goals with personal values, and boosting morale across the organization. For example, our Near Dear Program, a unique Haleon Canada program, allows employees to nominate up to two non-profit organizations per quarter to receive $5,000 each, totaling $40,000 per year. This allows Haleon to make a meaningful contribution to organizations that are important to individuals. These are often organizations that have had a direct impact on their lives. Our employees also took a hands-on approach last year contributing a total of over 1,600 volunteer hours to local communities and packing over 1,000 wellness kits for refugees. By empowering our people to take charge, we’re not just making a difference in our communities; we’re also fostering a culture of engagement and purpose within Haleon. So, how are you empowering your employees to shape the future of community giving at your organization? #HaleonCanada #Purpose #CorporateSocialResponsibillity

62

5 commentaires

📖 "Read to Lead" : 6 must-read books that top pharma execs recommend 📝 Leadership inspiration can come from unexpected places, including novels, memoirs, and timeless philosophy. PharmaVoice listed 6 books pharma execs swear by : 1️⃣ "Babel" by R.F. Kuang - recommended by Court Horncastle, GSK. A thought-provoking fantasy novel that challenges assumptions and encourages a new way of thinking. 2️⃣ "The Daily Stoic" by Ryan Holiday & Stephen Hanselman - recommended by Katsuyoshi Sugita, Astellas Pharma. Daily meditations to cultivate wisdom, perseverance, and a balanced life—essential for any leader facing stress. 3️⃣ "The Emperor of All Maladies" by Siddhartha Mukherjee - recommended by Faye Feller, Geron. A captivating “biography of cancer” that provides insights into oncology drug development and the history of cancer research. 4️⃣ "Tough Choices" by Carly Fiorina - recommended by Heather Dean, Takeda Pharmaceuticals. A candid memoir of leadership, providing valuable lessons on navigating transitions and engaging directly with team members. 5️⃣ "Atomic Habits" by James Clear - recommended by Ian Thompson, Amgen. A powerful guide on how small, incremental improvements can lead to big changes in both personal and professional life. 6️⃣ "Ganbatte!" by Albert Liebermann - recommended by David A. Dodd, GeoVax. The Japanese philosophy of persistence: “Do your best, keep going, and never give up!” Impressive list. 2 of which I already read - the rest is now on my to do - and can confirm they are game changers. What’s your favorite leadership book? Let’s share! ——— I am Alexis - French pharmacist turned entrepreneur. My company BTHT is connecting senior industry experts, ex-payors, and KOLs with consultants and investors in Life Sciences and Healthcare for expert calls and senior advisory. 👇 For more content like this Join 15K+ followers by clicking my name + follow 🔔 Join 1.3K+ subscribers to my newsletter 💌

16

Today, we will explore various special regulatory pathways and their impact on the drug regulatory review process. [Simple yet complex] I will highlight the designations granted by the US FDA, along with their specificities. You can compare these with the equivalent EMA designations in the attached image. 1. Orphan Drug Designation (ODD): This designation includes benefits such as tax credits (25%), R&D grants, accommodating trial design during phase 2 & 3, reduced review fee with comprehensive regular FDA communications, and 7 years of market exclusivity 2. Fast Track Designation (FTD): This designation allows for more frequent communication with FDA and rolling FDA review starting from phase 2 (if successful, this phase 2, instead of phase 3, would, therefore, be sufficient to prove a drug’s safety and efficacy). Additionally, FDA may require a post-marketing trial to address uncertain side effects, toxicity, or treatment outcomes 3. Accelerated Approval (AA): This pathway allows the use of surrogate endpoints instead of regular clinical endpoints during phase 2 or/and 3. Just like FTD program, the FDA may require post-marketing trials for drugs approved under the AA program 4. Priority review: Guided by PDUFA, this program replaced a more complex system by prioritizing and allocating more resources to NDAs/BLAs based on their therapeutic gain. It expedites the review period, reducing it from the standard 10 months to 6 months for priority reviews. 5. Breakthrough designation (BTD): This designation offers advantages like adaptive trial design and the use of surrogate endpoints. It includes all fast track benefits along with early communication with the FDA starting from phase 1, meetings with senior FDA staff, and a cross-disciplinary project lead. However, the FDA may request a phase 4 trial

1

As the French government prepare to present their draft of the 2025 Social Security Financing Bill (PLFSS), Leem have been establishing recommendations to balance the preservation of the social protection model, whilst continuing to foster an attractive pharmaceutical market. Leem’s key proposals include capping the safeguard clause at €1.6 billion, and slowly decreasing this to €500 million by 2027, addressing the financial strain on both the French healthcare service and the pharmaceutical industry, and advocating for a medication policy that supports public health and the economic viability of the industry. Leem has warned of the weakening of the medicines value chain, and expresses concerns around lower access, innovation, and risks of shortages in France. To learn more about the proposed PLFSS for 2025, or understand how this may impact your organization, please reach out to me. Source: https://lnkd.in/e5ztwbwz

14

𝐁𝐫𝐢𝐝𝐠𝐢𝐧𝐠 𝐭𝐡𝐞 𝐆𝐚𝐩 𝐢𝐧 𝐖𝐨𝐦𝐞𝐧’𝐬 𝐇𝐞𝐚𝐥𝐭𝐡: 𝐀 𝐆𝐥𝐨𝐛𝐚𝐥 𝐈𝐦𝐩𝐞𝐫𝐚𝐭𝐢𝐯𝐞   Eager to share insights from McKinsey Health Institute recent analysis in collaboration with the World Economic Forum, #Closing #the #women’s #health #gap. This comprehensive study sheds light on the disparities in health outcomes for women worldwide and presents a compelling case for why closing this gap globally could result in better overall health, fewer early deaths, and a boost in the economy. 🌍 Over the past two centuries, global life expectancy has risen significantly. However, this success story doesn’t tell the whole truth. Women spend more of their lives in poor health, affecting their productivity and earning potential. On average, a woman will experience nine years of poor health, impacting her ability to contribute at home, in the workforce, and within the community. This disparity is known as the women’s health gap. 📊 #The #Numbers: 🌟 Women spend an average of #nine years in #poor #health, impacting their #presence and #productivity in all spheres of life. 🌟 The women’s #health #gap results in #75 #million years of #life #lost due to poor health or early death annually. 🌟 #Addressing this #gap could have the equivalent #impact of #137 #million women #accessing full-time #positions by #2040. 🌱 #Why #It #Matters: 🌟 Closing the health gap isn’t just about economics; it’s about #health #equity and #inclusivity. 🌟 Improving women’s health enhances #quality #of #life and positively #impacts #future #generations. 🚀 #Call #to #Action:  🌟 Let’s rally together! 🌟 Share the McKinsey report on bridging the women’s health gap. 🌟 Encourage policymakers, healthcare providers, and communities to prioritize women’s health. By doing so, we can create a healthier, more prosperous world for everyone. #The #Responsibility #of #Taking #Action #is #on #Us Read the Full Study: https://lnkd.in/ectMnFe9 #WomenInHealth #HealthEquity #EmpowerWomen 

7

1 commentaire

Interesting slide from the Reuters Events Pharma 2024 report. 📈 Only 6% of respondents felt that their organisation is leading the way in the personalisation of customer engagement. 😬 The industry can do better and clearly wants to do better. So, what’s stopping leaders from helping their teams to grasp omnichannel? Why isn’t the industry as a whole tailoring messages to suit the HCPs? Imagine the difference it would make to the customer experience. Be the change! The first easy step to personalisation is increasing the capability of the field team to adopt to HCP preferences. We know a thing or two about this topic! Want to learn more? Reach out for a chat, or read The Omni Advantage. #Pharma #Omnichannel #PharmaLeader

22

9 commentaires

I like Sanofi's smart manufacturing strategy: 🎀 News of its ribbon cutting ceremony for a new biologics and vaccine manufacturing plant in Neuville-sur-Saône, France. 🏭'Modulus' contains 34 "mini-factories" capable of reconfigurations or modifications to production lines within weeks (much faster, compared to other traditional, industrial methods), pending dynamics or needed shifts up or down, to any of the up to four vaccines or biologics that it can manufacture simultaneously 🗓 Estimated online and operational in CY2025 The French drug-maker has recently made a sizable investment in insulin production in Germany, as well as doubled manufacturing capacity at another site in France. https://lnkd.in/ejz9auYX. #Strategy #Pharma #Sanofi #Manufacturing #Vaccines #mABs #mRNA #Healthcare

2

There is clearly a slowly down of the hype around GenAI and this is actually a good thing ! We can now focus the discussion on what is needed to bring production ready and responsible solutions to key challenges in the healthcare industry. A few indicators that hints our teams and collaborators are trailblazing the right path… 1. The project sparks interest across different departments, breaking down internal silos. 2. The work contributes to setting the foundation for responsible AI practices. 3. The insights gained can be applied across various industries These are a few examples I am looking forward to share when connecting with fellow data and AI enthusiast across industries at the next Big Data London conference. https://lnkd.in/de67nZqt #BigdataLDN #NovoNordisk #DataScience Rasmus Sten Andersen Georg Kavousanos Peter Vester Kristine Deibler Tonia Sideri Dorota Loza-Ioannoglou Mimmi Gersbro-Sundler Siddhant Prabhu Jakob Mainz, PhD Thomas Senderovitz Stephanie Bova Valdemar Borum Svarrer Gabriela Simon Loïc Giraud Guillaume Carbonneau Big Data LDN

149

6 commentaires

TLDR Biotech for June 27 - 30 𝐀𝐩𝐩𝐫𝐨𝐯𝐚𝐥𝐬: AstraZeneca, Sanofi's infant RSV vaccine gets thumbs-up from German vaccine advisory panel 💉 + 3 more stories 𝐁𝐮𝐬𝐢𝐧𝐞𝐬𝐬 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭: Lantheus purchases two radiopharmaceutical assets from Life Molecular Imaging 💼 𝐂𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐓𝐫𝐢𝐚𝐥𝐬: J&J touts stellar Ph3 myasthenia gravis results 🧪 + 1 more story 𝐂𝐨𝐦𝐩𝐚𝐧𝐲 𝐋𝐚𝐮𝐧𝐜𝐡𝐞𝐬: Ensho Therapeutics launches with assets acquired from Eisai 🚀 𝐅𝐮𝐧𝐝𝐫𝐚𝐢𝐬𝐞𝐬: Savara $100M underwritten offering 💰 + 2 more stories 𝐋𝐚𝐰𝐬𝐮𝐢𝐭𝐬: Daiichi-Sankyo wins patent dispute against Seagen (Pfizer) ⚖️ 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐩𝐨𝐫𝐭𝐬: Analysts predict change in Osteoporosis market winds; Amgen punching air 📊 𝐏𝐚𝐭𝐢𝐞𝐧𝐭 𝐀𝐜𝐜𝐞𝐬𝐬: CMS provides details on cell & gene therapy access pilot 🏥 𝐑𝐞𝐠𝐮𝐥𝐚𝐭𝐨𝐫𝐲: Supreme Court overturns Chevron doctrine, potential FDA ramifications 🏛️ All this and more in today's TLDR Biotech newsletter - link to the latest issue: https://lnkd.in/gign9-Sw Or subscribe to get it straight to your inbox: https://lnkd.in/gh68uhTQ #tldrbiotech #biotechnews #pharmanews

11

don't forget to register. Learn how you can get involved in true value chain transformation

1

Thoughts on this? >> French Markets Slide As Nation Plunged Into Political Turmoil >> Comment below! >>> lqventures.com #digitalhealth #socialmedia #digitalmarketing #IoT #industry40 #AI #healthtech #mhealth

1

Achondroplasia Market is Expected to Show a Significant Growth During the Forecast Period | Pfizer, Sanofi, ProLynx, PhaseBio, Ascendis, BioMarin: Achondroplasia Market According to DelveInsight, the dynamics of the Achondroplasia market are expected to shift in the coming years due to the introduction of new emerging drugs, government backing for clinical development, and a rising number of Achondroplasia cases across … Continue reading → #Business #Europe #HealthMedicine #PharmaceuticalsBiotech #US

1

Imagine someone telling you “#AI will make your job disappear 🫥 but it’s OK because it shouldn’t have existed in the first place 😱”! That’s arrogant or insensitive to say the least … but it raises the question 🙋‍♀️ on how manage the transition and training of those impacted by AI 🤖. Implementing AI takes time 🕰️ hence it gives organisations plenty of time to retrain those impacted. This should be an integral part of any AI plans.

9

Just discovered a very good read on Responsible AI 🌟. It's a goldmine for understanding the latest in #AI ethics and innovation. Highly recommend it for anyone in 🤖 #ResponsibleAI #FutureOfTech

3